Prostate Cancer

A study of the Veterans Affairs health system found that, despite trends suggesting otherwise, African American men with prostate cancer had similar survival outcomes, compared with non-Hispanic White men.

Researchers found that men with prostate cancer who consumed a diet high in vegetable did not experience clinical benefit; however, overall health benefits were seen.

How providers communicate medical bills to payers and patients, mandated by the US Centers for Medicare & Medicaid Services, still did not help patients and health care professionals in understanding differences in cost.

Researchers found that combining family history and genetic risk scores to determine inherited risk for prostate cancer could personalize screening strategies for men.

A modified citrus pectin, naturally found in the peel of citrus fruits, showed continued benefit among men with prostate cancer.

Men with metastatic castration-sensitive prostate cancer will now have a fourth treatment option to consider.

The Food and Drug Administration approved Xtandi for the treatment of patients with metastatic castration-sensitive prostate cancer.

New research suggests men with infertility could face a 30% to 60% higher risk of prostate cancer.

Although one in nine men will receive a prostate cancer diagnosis in his lifetime, cutting-edge research has allowed more men to live longer or even be cured.

Following a prostate cancer diagnosis, one survivor ditches the ‘macho man’ attitude for a lighter approach to life.

In order to turn your prostate cancer into a couch potato and keep it from spreading, your best chance is not to be one yourself.

During the 2019 Prostate Cancer Consensus Conference, one expert discussed three clinical trials and the future of genetic testing in patients with the disease.

We've got a sneak peek at what’s inside CURE®'s 2019 Genitourinary Cancers special issue.

Recent changes to the National Comprehensive Cancer Network (NCCN) guidelines around prostate cancer have updated the indications for genetic testing and have opened up a broader discussion on how it can be used to improve prostate cancer detection and treatment, according to Dr. James Mohler.

Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.

In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

Here is a list of the recent trial initiations that occurred within the cancer space in September.

For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.

A phase 3 trial showed a 33% reduction in the risk of death when patients were treated with Erleada compared with placebo.

I encourage men to be more knowledgeable of their family history and to potentially begin testing for prostate cancer earlier if you have a family history of the disease.

Here is a list of the recent trial initiations that occurred within the cancer space in August.

Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.

The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.